Novo Nordisk's CagriSema Shows 25% Weight Loss in Women, but FDA Verdict Is the Real Test

Novo Nordisk has rolled out a fresh set of CagriSema analyses focused on women living with overweight or obesity, posting a 25.0% average weight reduction after 68 weeks against 3.0% on placebo. The figures, presented at the annual meeting of the Menopause Society, add clinical ballast to the company's obesity franchise. They do not, however, move the needle on the one event that matters most to shareholders: a US regulatory ruling that is still pending.

The Danish drugmaker filed its US marketing application in December 2025 and is steering toward a US launch in early 2027. That timeline rests entirely on a positive FDA decision, which is anticipated in the fourth quarter of 2026. CagriSema, a once-weekly injection pairing semaglutide with cagrilintide, has yet to win approval in the US, and regulators have not signed off on its safety or efficacy.

What the 25% Figure Actually Measures

The headline number comes with a caveat that deserves as much attention as the result itself. The estimate assumes continuous treatment with no add-on weight-loss medication. That is a different question from an analysis that accounts for patients who stop therapy or turn to other drugs — and the gap between the two is instructive.

Across the full REDEFINE 1 trial, which enrolled 3,417 adults without type 2 diabetes, CagriSema produced an estimated 22.7% weight loss under continuous treatment. Once discontinuations and supplementary obesity medications are factored in, that figure settles at 20.4%. Investors would be wise not to lean on the most flattering efficacy number in isolation; both views of the data carry weight in assessing the drug.

The women's analysis covered 2,309 participants and went beyond the scale. Waist circumference fell by an average of 20.5 centimetres on CagriSema versus 4.7 centimetres on placebo. A full 68.7% of treated women shed at least 20% of their body weight, compared with 1.8% in the placebo arm — a spread that underscores the depth of the effect within the studied group.

Menopause Subgroups: Signals, Not Conclusions

Breaking the data down by menopausal status, average weight loss reached 26.7% before menopause, 24.8% during the transition and 23.1% after it. The decline across stages looks tidy, but it cannot be read as a confirmed difference in how the drug performs.

Menopausal status was reconstructed retrospectively rather than measured prospectively or verified biochemically, and the analysis of 1,902 women was exploratory with no formal between-group comparison. Novo itself says further research is needed to test the hypotheses the breakdown has generated. The subgroup findings point toward future study; they do not establish that menopausal status governs CagriSema's effect.

Tolerability and the Broader Safety Picture

Gastrointestinal complaints dominated the side-effect profile. Across the entire REDEFINE 1 study, 79.6% of participants on CagriSema reported such events, against 39.9% on placebo. Discontinuations due to adverse events came in at 5.9% for CagriSema and 3.5% for placebo.

Those figures apply to the full trial population and should not be mistaken for a separate safety readout on the women's subgroup. Nor do strong efficacy results stand in for a regulatory weighing of benefits against risks — that judgment remains with the FDA.

The Revenue Case Rests on More Than a Headline

Expectations already stretch past the approval decision. The FactSet consensus pencils in USD 11.84 billion in CagriSema obesity revenue for 2028 — a forecast, not booked income. Hitting it requires not just impressive weight loss but a green light from regulators and a successful commercial rollout.

For now, the women's data sharpen the clinical case for CagriSema while leaving the methodological limits of post-hoc analysis and the approval risk firmly in place. The next proof point Novo must deliver will come not from a conference podium but from the FDA review process.